Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer

Urology

Volumn 50, Issue 1, 1997, Pages 93-99

  Dillioglugil, Özdal ^b   Leibman, Bryan D ^b   Kattan, Michael W ^b   Seale Hawkins, Carie ^b   Wheeler, Thomas M ^b   Scardino, Peter T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURGICAL RISK;

ADENOCARCINOMA; ADULT; AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 0030757402     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00106-4     Document Type: Article

References (24)

1. National Institutes of Health Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. Bethesda, Md, June 15-17, 1987. NCI Monogr 7: 1-174, 1988.
2. Gibbons RP, Correa RJ Jr, Brennen GE, and Mason JT: Total prostatectomy for localized prostatic cancer. J Urol 131: 73-76, 1984.
3. Walsh PC, and Jewett HJ: Radical surgery for prostatic cancer. Cancer 45: 1906-1911, 1980.
4. Stein A, deKernion JB, Smith RB, Dorey F, and Patel H: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally confined extensive prostate cancer. J Urol 147: 942-946, 1992.
5. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, and Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850-1857, 1994.
6. McBride CM, Brown BW, Thompson JR, Westbrook KC, and Milne CA: Can patients with breast cancer be cured of their disease? A sample of the M. D. Andersen Hospital experience. Cancer 51: 938-945, 1983.
7. Ohori M, Wheeler TM, and Scardino PT: The new American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Cancer 74: 104-110, 1994.
8. Wheeler TM: Anatomic considerations in carcinoma of the prostate. Urol Clin North Am 6: 623-634, 1989.
9. Leibman BD, Dillioglugil O, Wheeler TM, and Scardino PT: Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 76: 2530-2534, 1995.
10. Kaplan ID, Cox RS, and Bagshaw MA: Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J Urol 149: 519-522, 1993.
11. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713-725, 1993.
12. Trapasso JG, deKernion JB, Smith RB, and Dorey F: Incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152: 1821-1825, 1994.
13. Takayama TK, Krieger JN, True LD, and Lange PH: Recurrent prostate cancer despite undetectable prostate specific antigen. J Urol 148: 1541-1542, 1992.
14. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, and Scardino PT: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152: 1843-1849, 1994.
15. Lashner BA, Silverstein MD, and Hanauer SB: Hazard rates for dysplasia and cancer in ulcerative colitis: results from a surveillance program. Dig Dis Sci 34: 1536-1541, 1989.
16. Fisher B, Bauer M, Wickerham DL, Redmond CK, and Fisher ER: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer 52: 1551-1557, 1983.
17. Hanks GE, Krall JM, Hanlon AL, Asbell SO, Pilepich MV, and Owen JB: Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys 28: 39-45, 1994.
18. Zincke H, Bergstralh EJ, Blute ML, Myers RP, Barrett DM, Lieber MM, Martin SK, and Oesterling JE: Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol 12: 2254-2263, 1994.
19. Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, and Scardino PT: Hazard rates for progression, determined by PSA, after radical prostatectomy for T1-2 prostate cancer (abstract 649). J Urol 153: 391A, 1995.
20. Scardino PT: Rationale for the treatment of clinically localized prostate cancer. Eur Urol 27: 17-20, 1995.
21. Dillioglugil O, Miles B, and Scardino FT: Current controversies in the management of localized prostate cancer. Eur Urol 28: 85-101, 1995.
22. Katz AE, Olsson CA, Raffo AJ, Cama C, Pearlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, and Buttayan R: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43: 765-775, 1994.
23. 111indium-labeled monoclonal antibody CYT-356. J Urol 152: 1952-1955, 1994.
24. Dwyer AJ, Prewitt JM, Ecker JG, and Plunkett J: Use of the hazard rate to schedule follow-up exams efficiently: an optimization approach to patient management. Med Decis Making 3: 229-244, 1983.